Wedbush Predicts Stronger Earnings for Denali Therapeutics

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities research analysts at Wedbush increased their Q2 2025 EPS estimates for Denali Therapeutics in a note issued to investors on Wednesday, May 7th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.76) for the quarter, up from their previous estimate of ($0.77). Wedbush currently has a "Outperform" rating and a $30.00 price target on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. Wedbush also issued estimates for Denali Therapeutics' FY2025 earnings at ($3.17) EPS, Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($3.16) EPS, FY2027 earnings at ($2.77) EPS and FY2028 earnings at ($1.10) EPS.

A number of other brokerages have also recently issued reports on DNLI. HC Wainwright dropped their target price on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft began coverage on shares of Denali Therapeutics in a report on Tuesday, February 11th. They issued a "buy" rating and a $31.00 target price on the stock. Bank of America cut their target price on shares of Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a report on Monday, March 10th. Cantor Fitzgerald raised shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Thursday, April 10th. Finally, Oppenheimer lowered their price objective on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Denali Therapeutics has a consensus rating of "Buy" and an average target price of $33.79.

Denali Therapeutics Stock Performance

Shares of DNLI stock traded down $0.30 during mid-day trading on Monday, reaching $13.96. The company's stock had a trading volume of 1,170,551 shares, compared to its average volume of 1,095,969. Denali Therapeutics has a 1-year low of $10.57 and a 1-year high of $33.33. The company has a market cap of $2.03 billion, a P/E ratio of -5.06 and a beta of 1.49. The firm's 50-day moving average is $14.20 and its two-hundred day moving average is $19.87.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same period last year, the business posted ($0.68) EPS.

Institutional Trading of Denali Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Sterling Capital Management LLC lifted its holdings in shares of Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after acquiring an additional 1,516 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in Denali Therapeutics by 277.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock valued at $29,000 after purchasing an additional 1,551 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Denali Therapeutics during the 1st quarter valued at $41,000. GF Fund Management CO. LTD. acquired a new stake in shares of Denali Therapeutics during the fourth quarter valued at about $62,000. Finally, Point72 Hong Kong Ltd acquired a new stake in Denali Therapeutics during the 4th quarter worth approximately $65,000. Institutional investors own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.